Carcinoma of the prostate in Israel: some epidemiological and therapeutic considerations.
Analysis of the different rate of prostatic cancer in Israel among Jews from various countries of origin reveals some very interesting and marked varieties in incidence, which are studied more closely now. Aggressive, combined treatment for the invasive cases of prostatic cancer has been used since 1975. This was based on orchiectomy, DES, and chemotherapy for the stage D2 disease, and on radiotherapy and hormonal therapy for the stage C, and possibly also the stage D1 disease. Results so far have been very encouraging indeed, and with considerably better results than obtained with the individual, more conventional forms of therapy. Five-year survival in the stage D2 disease has been 63.5%, and 87.6% in the stage C (+D1?) disease. It appears that this approach is more justified, certainly in the advanced stages of this disease.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001208:Asia / Q000208:ethnology; D002369:Castration; D003131:Combined Modality Therapy; D004054:Diethylstilbestrol / Q000627:therapeutic use; D005060:Europe / Q000208:ethnology; D005500:Follow-Up Studies; D006801:Humans; D007557:Israel; D007585:Jews; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy; D013997:Time Factors
D004054:Diethylstilbestrol